Related Experiment Video
Updated: Dec 30, 2025
06:46
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
Cognitive and behavioral status in Japanese ALS patients: a multicenter study.
Yasuhiro Watanabe1, Joost Raaphorst2, Yuishin Izumi3
1Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan. yawatana@tottori-u.ac.jp.
Journal of Neurology
|January 20, 2020
Summary
Cognitive impairment is common in Japanese Amyotrophic Lateral Sclerosis (ALS) patients, often exceeding behavioral changes. Early clinical attention to these diverse cognitive and behavioral aspects in ALS is crucial.
Area of Science:
- Neurology
- Neuropsychology
- Clinical Neuroscience
Background:
- Amyotrophic Lateral Sclerosis (ALS) can present with cognitive and behavioral deficits mirroring Frontotemporal Dementia (FTD).
- Understanding these deficits in Japanese ALS patients is essential for comprehensive care.
Purpose of the Study:
- To characterize cognitive and behavioral abnormalities in Japanese ALS patients.
- To explore associations between these impairments and motor function, anxiety, and depression.
Main Methods:
- Multicenter study involving 145 Japanese ALS patients.
- Evaluations included MoCA, FAB, HADS, ALSFRS-R, spirometry, verbal fluency tests, and caregiver ALS-FTD-Q.
- Defined cognitive and behavioral impairment using established scoring criteria.
Main Results:
- Approximately 70% of ALS patients exhibited mild or severe cognitive impairment.
- Cognitive impairment was five times more prevalent than behavioral impairment.
- Worse behavioral scores correlated with longer disease duration and higher anxiety/depression levels.
Conclusions:
- High prevalence of cognitive impairment in Japanese ALS patients necessitates greater clinical focus.
- The diversity of cognitive and behavioral impairments requires tailored clinical attention.
- Early identification and management of these aspects are vital for patient care.
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:22Alzheimer's Disease: Treatment
707
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
707